逆戻りできないアゴニスト-β(2) アドレノ受容体複合体の構造と機能
Daniel M Rosenbaum1, Cheng Zhang, Joseph A Lyons
1Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 279 Campus Drive, Stanford, California 94305, USA.
Nature
|January 14, 2011
まとめ
研究者らは,ベータ-2アドレネルゲン受容体 (β(2) AR) の新しい共性アゴニストを開発した. これにより,受容体が安定した.
科学分野:
- 構造生物学 構造生物学とは
- バイオケミストリー バイオケミストリー
- 分子薬理学 分子薬理学
背景:
- Gタンパク質結合受容体 (GPCR) は重要な細胞シグナル伝達タンパク質ですが,アゴニストの結合メカニズムは不明です.
- GPCRの活性化を理解することは,薬剤設計の鍵ですが,アゴニスト結合状態の結晶化は,弱いリガンド相互作用のために困難です.
- 人間のβ-2アドレネルゲン受容体 (β(2) ARはよく研究されたGPCRですが,その活性構成は構造的に捕捉することが困難です.
研究 の 目的:
- アゴニストに結合したGPCRの高解像度構造を決定する.
- GPCRの活性化とアロステル調節の分子基礎を解明する.
- 新規のGPCRを標的とする治療法の構造誘導設計を可能にする.
主な方法:
- ディスルファイド結合で結合されたβ(2) ARの新型共性アゴニストの設計と合成.
- Gタンパク質の活性化を行うことができる安定した共性 β(2) AR-アゴニスト複合体の形成.
- 脂質二重層における共性アゴニスト結合β(2) AR-T4L融合タンパク質の結晶化は,脂質メソファーゼ法を用いて行われます.
- 3.5 Åの解像度で複合体の構造を決定する.
主要な成果:
- 安定した共振性アゴニストに結合したβ(2) AR複合体が成功裏に生成され結晶化されました.
- 構造分析により,受容体の活性構造が明らかになり,細胞外と細胞内の両面での相互作用が求められます.
- 分子ダイナミクスシミュレーション (最大30μs) は,Gタンパク質または安定化抗体なしで活性状態の不安定性を示しました.
結論:
- 協和性アゴニスト戦略は,アゴニストに結合したGPCRを結晶化するための課題を克服します.
- 決定された構造は,β(2) AR活性化に必要な構造変化に関する重要な洞察を提供します.
- この研究は,GPCRの活性化メカニズムの理解を深め,構造に基づく薬剤発見を促進します.
関連する概念動画
Drug-Receptor Interaction: Agonist
4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Drug-Receptor Interaction: Antagonist
4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Combined Effects of Drugs: Antagonism
11.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K


